Navigation Links
Molecule responsible for age associated macular degeneration identified

CLEVELAND--A dart-like molecule that sticks to proteins in the eye is the main trigger for the unchecked growth of blood vessels, according to researchers at Case Western Reserve University and the Cleveland Clinic Cole Eye Institute. //Uncontrolled blood vessel growth is one of the main reasons for the development of age-related macular degeneration (AMD), the leading cause of blindness among people over 65 in the United States.

Robert Salomon and his graduate students Kutralanathan Renganathan and Liang Lu of Case's Department of Chemistry in the College of Arts and Sciences, found that the molecule, Carboxyethylpyrroles (CEPs), attaches to proteins found in the eye, triggering the uncontrolled growth of blood cells.

The Case researchers teamed up with Quteba Ebrahem Jonathan Sears, Amit Vasanji, John Crabb and Bela Anand-Apte and Xiaorong Gu (a Salomon group alumna), of Cleveland Clinic, to complete the study titled Carboxyethlpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration.'

The results of their collaborative work were published in the recent Proceedings of the National Academy of Science (PNAS).

AMD is a progressive disease that results in the severe loss of vision. The early stages of AMD are characterized as 'dry,' with the disease advancing to the 'wet form' as the retina, the part of the eye responsible for central vision, becomes infused with fluid from leaky new blood vessels, during a process called neovascularization. The unchecked blood vessel growth, or angiogenesis, in the retina accounts for 80% of the vision loss in the advanced stages of AMD.

The retina cells that detect light contain polyunsaturated fatty lipids that are exquisitely sensitive to damage by oxygen. Even in healthy eyes, these cells are renewed every ten days. The researchers at Case and Cleveland Clinic used a method developed by Salomon to specifical ly detect and measure the amount of CEPs found in the eye.

The researchers did in vivo animal studies with membranes from chicken eggs and rat eyes and found that CEPs attached to proteins induce angiogenesis. They also found that the protein part of CEP-protein adducts is not important for producing the growth of the blood vessels. Rather, the actual CEP is the cause of angiogenesis.

In an attempt to block CEP from triggering the angiogenesis process, 'we are now trying to find the receptors – the keyholes – in the retina cells that are activated by CEPs,' said Salomon. 'We are also designing drugs that can mop up the CEPs or prevent their formation.'

The research is supported by an Ohio Board of Regents Biomedical Research Technology Transfer Award to the Cole Eye Institute, National Institutes of Health Grants as well as the Foundation Fighting Blindness and the American Health Association.

For more than three decades, Salomon has worked in the area of lipid research. His work centers on the oxidation of lipids in the body that contributes to a host of diseases including glaucoma, keratitis and other eye diseases as well as Alzheimer's disease, atherosclerosis, autism and end-stage renal disease. He discovered many chemical transformations that occur as a result of lipid oxidation, and generated some of the first molecular tools that have been used in clinical studies relating the hardening of the arteries in heart disease. In the hope of preventing the formation of toxic molecules in the eye, through the combination of oxygen with lipids, Salomon is now studying the processes that generate them with a new grant from the National Eye Institute of the National Institutes of Health.



Source-Eurekalert
SA
'"/>




Related medicine news :

1. New Molecule that can stop the growth of Viruses
2. Puberty may be due to GPR54 gene and KiSS-1 Molecule
3. Molecule responsible for muscle repair identified
4. Molecule aids fight E. Coli Infections
5. Molecule That Aids Bacterial Infections Identified
6. Molecule Behind Multiple Sclerosis Discovered
7. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
8. Scientists Discover Prostate Cancer Triggering Molecule
9. Passion Fizzling Out? Blame The “Love Molecule
10. Sensor Can Detect "Unhealthy" Molecules In Breath
11. Polymer Molecule Layered On Carb Molecule to Increase Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... 05, 2016 , ... BSI and Brenntag Canada have been appointed by Chr. ... of their natural fruits and beverage colorants effective November 1, 2016. ... our Life Sciences product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... TCS was previously a subsidiary of Chiltern International and focuses on ...
(Date:12/5/2016)... ... ... The new knee compression sleeves come as a pair which will provide ... lifting and any sport that requires knee compression or protection from the demands ... higher quality knee sleeve performance. Firstly it is made out of premium 7mm thick ...
(Date:12/5/2016)... OH (PRWEB) , ... December 05, 2016 , ... ... engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy of ... in various healthcare settings. , Over the last 60 years, studies have ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response ... and tolerability profile of ropeginterferon alfa-2b versus HU ... ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization ... present this data to the FDA as it seeks approval ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... 3, 2016   Pairnomix, LLC, a genetic research ... recognized by the White House, today announced that findings from ... identification of candidate therapies for a patient with epileptic encephalopathy ... were presented at the 70 th Annual Meeting of ... TX , December 2-6, 2016.  Pairnomix, unique ...
Breaking Medicine Technology: